What changed from existing technology?
This study compared two types of mouse tumors using a technique that measures proteins to understand how they differ and how immune cells might be involved.
This is the first study to use label-free quantitative proteomics for immune cell deconvolution in murine tumor models, revealing distinct proteomic profiles between CT26 and KPC tumors.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
spite their extensive use, their proteomic landscapes remain insufficiently characterized. We applied label-free quantitative proteomics to KPC and CT26
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Early research
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The findings may help in understanding tumor heterogeneity and developing more targeted cancer therapies based on proteomic profiles.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.